Temple Lung Center: Advancing Research in ILD - Scorecard - MDSpire

Temple Lung Center: Advancing Research in ILD

  • By

  • April 28, 2025

  • 2 min

Share

Clinical Scorecard: Temple Lung Center: Advancing Research in ILD

At a Glance

CategoryDetail
ConditionInterstitial Lung Diseases (ILD)
Key MechanismsImpact on patient morbidity and mortality; involvement of connective tissue diseases.
Target PopulationPatients with various forms of ILD, including idiopathic pulmonary fibrosis and scleroderma-related ILD.
Care SettingILD Center of Excellence with comprehensive evaluation and management programs.

Key Highlights

  • Comprehensive programs for evaluation and management of ILDs.
  • Expertise in lung transplantation for patients with esophageal dysfunction.
  • Innovative clinical trials focusing on targeted therapies.
  • Experience in transplants for various ILDs related to connective tissue diseases.
  • Active enrollment in clinical trials for patients with progressive pulmonary fibrosis.

Guideline-Based Recommendations

Diagnosis

  • Comprehensive evaluation of ILD patients at specialized centers.

Management

  • Utilization of targeted therapies via inhaled, oral, or subcutaneous routes.

Monitoring & Follow-up

  • Regular assessment of lung function and disease progression.

Risks

  • Morbidity and mortality associated with untreated ILDs.

Patient & Prescribing Data

Patients with idiopathic pulmonary fibrosis, scleroderma-related ILD, and other connective tissue disease-related ILDs.

Participation in clinical trials for innovative therapies is encouraged.

Clinical Best Practices

  • Engage patients in clinical trials for cutting-edge treatment options.
  • Utilize a triage map to identify appropriate studies for patients.
  • Provide comprehensive care through specialized ILD centers.

References

Original Source(s)

Related Content